MarketArne Astrup
Company Profile

Arne Astrup

Arne Vernon Astrup is a Danish nutritionist, chief physician, researcher, author and professor. He is known as a researcher, communicator and author and has published more than 900 scientific articles. In 2018 he was internationally recognised as one of the world's most cited researchers. Arne Astrup has contributed to the identification of GLP-1 as a satiety hormone, which has played a key role in the development of GLP-1 drugs for the treatment of obesity, which has contributed to the success of Novo Nordisk A/S and their drug Wegovy.

Career and recognitions
Arne Astrup has achieved national and international recognition since the 1990s. He is known for being one of the most cited researchers in the world. that have made his name publicly known in the wider Danish population. Recognitions Public attention: In the 1990s, Arne Astrup gained public attention due to his new methods for measuring appetite and energy intake. • Chairman of the National Nutrition Council: From 1993 to 2001, he was the chairman of the National Nutrition Council (replaced by the Council for Physical Activity and Nutrition in 2005) and contributed to the ban on industrially produced trans fats in Denmark in 2004. • Academically active for 30 years: During an academic career spanning 30 years, Arne Astrup has primarily focused on research in appetite regulation, treatment of obesity, type 2 diabetes, cardiovascular diseases, and other conditions where nutrition and physical activity are significant. • GLP-1 as a satiety hormone: In 1996, together with Jens Juul Holst, he identified GLP-1 as a satiety hormone, leading to a patent that helped Novo Nordisk A/S develop GLP-1 analogs for severe obesity. • World Obesity Federation: Astrup was president of the World Obesity Federation for four years (formerly The International Association for the Study of Obesity (IASO)). • OPUS Centre: Director of the OPUS Centre ("New Nordic Everyday Food") supported by the Nordea Foundation with DKK 100 million (2009–2014). • Obesity Reviews: Arne Astrup was the founding editor-in-chief of the English journal Obesity Reviews (from 1999 to 2010). • American Journal of Clinical Nutrition: Editor of the American Journal of Clinical Nutrition since 2010. • Shanghai Rankings: Under his leadership, the Department of Sports and Nutrition at the University of Copenhagen was recognised as the world's leading institution in sports research by the Shanghai Ranking in 2018. • 900+ scientific articles: He has published more than 900 peer-reviewed scientific articles and over 1000 other academic texts, including abstracts, textbook chapters, and scientific letters. • '''Among the world's most cited:''' Arne Astrup is internationally recognised as one of the world's most cited researchers. In 2018 Clarivate’s (Web of Science) named him among the most cited researchers in the world. • Knight of the Order of the Dannebrog: Knight of the Order of the Dannebrog in 1999, and Knight 1st Class of the Order of the Dannebrog in 2012. == Arne Astrup's research ==
Arne Astrup's research
Arne Astrup has a background in nutrition research, where he has worked with both experimental physiological and biochemical research as well as clinical treatment trials with subjects and patients. His scientific work has contributed to the understanding of human appetite regulation and energy metabolism, which has led to insights into adipose tissue deposition and body weight. == GLP-1 as a satiety hormone in humans ==
GLP-1 as a satiety hormone in humans
In collaboration with Professor Jens Juul Holst, he discovered that GLP-1 acts as a satiety hormone in humans. supported by the EU Framework Program with 15 million euros, which showed that a diet with more protein and fewer carbohydrates could promote weight control in overweight people after weight loss. Together with Master of Science in Human Nutrition Christian Bitz, he has disseminated the principles of Diogenes in the book “''The World's Best Diet''”, which has sold over 100,000 copies and has been translated into 4 languages. == Criticism and Controversies ==
Criticism and Controversies
Astrup has faced criticism for combining his research responsibilities with personal economic interests on several occasions. For instance, he held a dual role with the company Neurosearch, acting as an advisor and owning stocks while publicly endorsing the company’s diet pill in his column, "Doktor Slank" ("Doctor Skinny"). This raised concerns about potential conflicts of interest. Following the negative publicity, Astrup sold his shares in Neurosearch, which were valued at approximately DKK 200,000. He maintains that he was able to keep his professional and personal interests separate. A person who divided the public In public, Arne Astrup has been controversial over the years, and as a public figure he shares the waters. Some view Arne Astrup positively and value his scientific merits and popular impact in translating complex science into easily understandable messages. Others were critical and saw him as untrustworthy, partly on the grounds that he collaborated closely with industry, and that his scientifically based messages have often been so closely aligned with the interests of those who funded his research that he could be bought to say anything. == Career after academia ==
Career after academia
After eight years (2012-2020) as the head of the Department of Nutrition, Exercise and Sports at the University of Copenhagen, Arne Astrup left the position on July 1, 2020 as he was appointed Senior Vice President and Head of the Obesity and Nutritional Sciences department at the Novo Nordisk Foundation where he has been responsible for leading a national initiative, which aims to prevent obesity and poor well-being in children. Arne Astrup is a member of the Foundation's Executive Leadership Team. == Awards and honours ==
Awards and honours
Arne Astrup has received a number of Danish and international awards throughout his career, including: == Authorship ==
Authorship
Arne Astrup has published several books together with other authors such as Claus Meyer, Christian Bitz, Mads Fiil Hjorth and others. == References ==
tickerdossier.comtickerdossier.substack.com